CoChat

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes

Kaku, K., Rasmussen, M. F., Clauson, P., Seino, Y. · 2010 · Diabetes, Obesity and Metabolism
Cited by 91

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aim: Sulphonylureas (SUs) are often used as first‐line treatments for type 2 diabetes in Japan, hence it is important to study new antidiabetic drugs in combination with SUs in Japanese patients. Methods: The efficacy and safety of the once‐daily human glucagon‐like peptide‐1 (GLP‐1) analogue liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m 2 ; mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or glimeprimide) in a 24‐week, double‐blind, parallel‐group trial. Results: The mean change in HBA1c from baseline to week 24 (LOCF) was −1.56 (s.d. 0.84) and −1.46 (s.d. 0.95) with liraglutide 0.9 and 0.6 mg respectively, and −0.40 (s.d. 0.93) with placebo. HBA1c decreased in the placebo group from 8.45 to 8.06%, while liraglutide reduced HBA1c from 8.60 to 7.14%, and from 8.23 to 6.67% at the 0.6 and 0.9 mg doses respectively. Mean HBA1c at week 24 of the two liraglutide groups were significantly lower than the placebo group (p < 0.0001 for both). More subjects reached HBA1c < 7.0% with liraglutide (0.6 mg: 46.5%; 0.9 mg: 71.3%) vs. placebo (14.8%). Fasting plasma glucose (FPG) levels were significantly improved with liraglutide (difference −1.47 mmol/l and −1.80 mmol/l with 0.6 and 0.9 mg vs. placebo; p < 0.0001). Overall safety was similar between treatments: no major hypoglycaemic episodes were reported, while 84/77/38 minor hypoglycaemic episodes occurred in the 0.6 mg/0.9 mg and placebo treatment groups (all in combination with SU), reflecting lower ambient glucose levels. No relevant change in mean body weight occurred in subjects receiving liraglutide (0.6 mg: 0.06 kg; 0.9 mg: −0.37 kg), while mean body weight decreased in subjects receiving placebo (−1.12 kg). Conclusions: The addition of liraglutide to SU treatment for 24 weeks dose‐dependently improved glycaemic control vs. SU monotherapy, without causing major hypoglycaemia or weight gain or loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2009.01194.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 24

  1. 10.1016/j.diabres.2003.11.024 · DOI · Paper page
  2. 10.1016/j.metabol.2004.02.012 · DOI · Paper page
  3. 10.2337/diab.46.1.63 · DOI · Paper page
  4. 10.1007/s00125-003-1158-9 · DOI · Paper page
  5. 10.1016/S0140-6736(03)15348-2 · DOI
  6. Japan Diabetes Society, 2006, Evidence based clinical practice guidelines for the treatment of diabetes mellitus in Japan, J Japan Diab Soc, 49, 409
  7. Kawamori R., 2003, Efficacy and safety of insulin glargine in concurrent use with oral hypoglycaemic agents for the treatment of type 2 diabetes patients, Rinsho Iyaku, 19, 445
  8. 10.1016/0168-8227(89)90116-2 · DOI
  9. Matsuzawa Y, 2002, Atarashii himan nohantei to himanshou no shindan kijun [The new diagnostic criteria of obesity], J Japan Soc Study Obes, 6, 18
  10. 10.1046/j.1467-789X.2002.00065.x · DOI · Paper page
  11. 10.1111/j.1464-5491.2006.02022.x · DOI · Paper page
  12. 10.1111/j.1464-5491.2009.02666.x · DOI · Paper page
  13. 10.2337/diabetes.52.7.1786 · DOI · Paper page
  14. 10.1016/j.diabres.2008.03.018 · DOI
  15. 10.1016/j.diabres.2006.01.013 · DOI
  16. 10.2337/diabetes.48.12.2358 · DOI · Paper page
  17. 10.1111/j.1600-051X.1988.tb01003.x · DOI · Paper page
  18. Russell‐Jones D, 2007, Insulin‐associated weight gain in diabetes—causes, effects and coping strategies, Diabetes Obesity Metab, 6, 799, 10.1111/j.1463-1326.2006.00686.x · DOI · Paper page
  19. 10.1210/jcem.82.12.4460 · DOI · Paper page
  20. Japan Society for the Study of Obesity, 2004, The Examination Committee of criteria for ‘Obesity Disease’ in Japan, Circ J, 66, 987
  21. Russell‐Jones D, 2008, The once‐daily human GLP‐1 analog liraglutide reduces body weight in subjects with type 2 diabetes, irrespective of body mass index at baseline, Diabetes, 57, A593
  22. Irie S, 2007, Safety, tolerability, pharmacokinetics, and pharmacodynamics of once‐daily GLP‐1 analogue liraglutide in healthy Japanese subjects, Diabetes, 56, A540
  23. 10.2337/diabetes.51.2.424 · DOI · Paper page
  24. Seino Y, 2007, Once daily dosing of the long acting GLP‐1 analog liraglutide significantly improves glycaemic control by reducing both fasting and post‐prandial glucose levels in Japanese subjects with type 2 diabetes, Diabetes, 56, A138

Cited by

See all 91

Metadata

Authors
Kaku, K., Rasmussen, M. F., Clauson, P., & Seino, Y.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2010-02-25
Volume
12
Issue
4
Pages
341-347
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2098905490
Cited by
91
References
10
FWCI
5.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2009.01194.x
The paper
Kaku, K., Rasmussen, M. F., Clauson, P., & Seino, Y. (2010). Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2009.01194.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.